Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.65 |
| ▸ | DRD3 | P35462 | 2/20 | 0.65 |
| ▸ | DRD1 | P21728 | 3/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.60 |
| ▸ | DRD5 | P21918 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1546980 | 0.90 | DRD2 (0.53) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL1546984 | 0.90 | DRD2 (0.53) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL7349653 | 0.83 | DRD3 (0.67) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL175904 | 0.81 | SLC18A3 (0.57) | DRD2DRD4CYP2D6 | |
| SCHEMBL10682052 | 0.80 | DRD2 (0.45) | DRD2DRD3 | |
| SCHEMBL7351986 | 0.80 | DRD2 (0.70) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL7382001 | 0.80 | DRD2 (1.00) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL21425396 | 0.78 | DRD2 (0.53) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL12125697 | 0.78 | DRD2 (0.76) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL12125694 | 0.78 | DRD2 (0.76) | DRD2DRD3DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0192521-B1 | 3-PHENYL-TETRAHYDROPYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL USE | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1988-12-14 | — | — | EP | claimed |
| EP-0192521-A1 | 3-Phenyl-tetrahydropyridine derivatives, process for their preparation and their therapeutical use | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1986-08-27 | — | — | EP | claimed |
| US-9139525-B2 | N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2015-09-22 | — | — | US | disclosed |
| EP-2146961-B1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | IVAX INT GMBH (CH) | 2014-01-29 | — | — | EP | disclosed |
| CN-101711236-B | N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2012-10-31 | — | — | CN | disclosed |
| CN-101711236-A | n-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2010-05-19 | — | — | CN | disclosed |
| US-20100105736-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-04-29 | — | — | US | disclosed |
| EP-2146961-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008127188-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | ALLBAY AB (SE) | 2008-10-23 | — | — | WO | disclosed |
| EP-0192521-B1 | 3-PHENYL-TETRAHYDROPYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL USE | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1988-12-14 | — | — | EP | disclosed |
| US-4663328-A | 3-Phenyl-tetrahydropyridine derivatives, and their use as sedative agents | LABORATOIRE L. LAFON (FR) | 1987-05-05 | — | — | US | disclosed |
| EP-0192521-A1 | 3-Phenyl-tetrahydropyridine derivatives, process for their preparation and their therapeutical use | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105736-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | CHRM4, GPR4, HTR4 | DRD2 66/4885DRD3 37/4885DRD1 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.